Tela Bio, a medical technology company in Malvern, is starting a transformation process two years after going public, writes John George for the Philadelphia Business Journal. 

“There’s going to be a shift in the company’s positioning and reason for being,” said Tela Bio CEO Antony Koblish. “We are expanding from being a soft tissue reconstruction company to a soft tissue preservation and restoration company.” 

The company is going to expand on its implants with a “holistic” array of products that work to preserve and restore soft tissue, help with healing, and drive better outcomes for patients. 

As part of its transformation, Tela Bio signed a distribution agreement with Next Science. This agreement gives Tela Bio exclusive rights to sell and market the Florida company’s proprietary antimicrobial surgical wash throughout the nation’s plastic reconstructive market.

Additionally, Tela Bio has first rights of negotiation for the European market, pending regulatory approvals for Next Science. 

Tela Bio already launched the first product from the deal, the SiteGuard No Rinse Antimicrobial Solution, and plans to release more creations later this year. 

“We’re not ready to talk about them yet, but there’s going to be a very nice cadence of new products,” Koblish said. 

Read more about Tela Bio in the Philadelphia Business Journal.